+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05399537

Safety Study of Prismocitrate 18 With PrisMax System for Anticoagulation During Continuous Renal Replacement Therapy

Led by Vantive Health LLC · Updated on 2026-10-05

40

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety of Prismocitrate 18, a solution used in continuous renal replacement therapy CRRT for patients with acute kidney injury AKI. This study also assesses the use of the PrisMax System Version 3.x with calcium line accessory, which includes software to help healthcare providers manage citrate anticoagulation during CRRT. The goal is to confirm safety and proper function of the system in a treatment setting. Participants will receive regional citrate anticoagulation RCA using Prismocitrate 18 during CRRT delivered by the PrisMax System Version 3.x with calcium line accessory. The Prismocitrate 18 solution is administered in pre-dilution mode, with dosing adjusted according to blood flow to reach target citrate and calcium levels. The study treatment period lasts up to 10 days. During the study, participants will be monitored closely for symptoms related to calcium imbalances and citrate accumulation from day 1 up to day 10. Safety assessments will continue through day 28 to track adverse events related to the treatment or procedure. Researchers will also observe how well the PrisMax System with RCA software supports correct dosing. Participants involvement includes clinical monitoring and laboratory tests throughout the treatment period.

CONDITIONS

Brief Title

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Research Team

G

Global CORP Clinical Trials Disclosure

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here